Antonio Mastroianni Valeria Vangeli Sonia Greco Luciana Chidichimo Filippo Urso Maria Vittoria Mauro Stefano Bonora Amedeo DE Nicolò Antonio D'Avolio
10.15167/2421-4248/jpmh2022.63.3.2137
J Prev Med Hyg
2022 Oct 27;63(3):E420-E423.
adverse drug reaction chronic hepatitis c direct-acting antiviral glecaprevir hcv hiv pibrentasvir
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/36415300/
HIV Infections / complications HIV Infections / drug therapy Hepatitis C, Chronic / complications Hepatitis C, Chronic / drug therapy Jaundice / chemically induced Jaundice / drug therapy
HIV Infections / complications HIV Infections / drug therapy Hepatitis C, Chronic / complications Hepatitis C, Chronic / drug therapy Jaundice / chemically induced Jaundice / drug therapy Case Reports Antiviral Agents / adverse effects Humans Hyperbilirubinemia / chemically induced Hyperbilirubinemia / drug therapy glecaprevir pibrentasvir Antiviral Agents
PMC9648555
36415300
Indirect hyperbilirubinemia and jaundice during chronic hepatitis C in an HIV-infected patient treated with glecaprevir/pibrentasvir (GLE/PIB) and antiretroviral therapy (ART). The first reported case in Italy
2022